About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432·40 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subjects chronically infected with HCV genotype 1 (Phase 2a and Phase 2b)
Subjects chronically infected with HCV genotype 4 (Phase 2b only)
HCV RNA viral load of ≥ 10\*5\* IU/mL at screening
BMI of 18 - 35 kg/m² at screening

You may not be if

Cirrhosis (Phase 2a only)
Decompensated cirrhosis (Phase 2b)
Co-infection with HBV or HIV
Hepatocellular carcinoma
Prior treatment with anti-HCV drugs

The record

StatusCompleted

PhasePhase 2

Taking part285

StartedFeb 2010

UpdatedOct 9, 2015

Conditions

Hepatitis C Virus

Where40

University Of Alabama At Birmingham
Birmingham, Alabama, United States
Alabama Liver & Digestive Specialists (Alds)
Montgomery, Alabama, United States
Florida Hospital Transplant Center
Orlando, Florida, United States

Clareo Health | Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin